Switzerland· 69553001
Andembry
A garadacimab product containing garadacimabum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Garadacimab is registered in 11 of 19 countries.
Countries holding a registration under ATC B06AC07 (garadacimab), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 7 of them publish a price we can compare per daily dose
Garadacimab · ATC B06AC07
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- garadacimabum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- B06AC07
- ATC class
- Garadacimab
- Defined daily dose
- 6.7 mg, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806955300181.2 mlCHF 16158.45
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Garadacimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaANDEMBRYCSL Behring GmbH, Marburg
- BelgiumAndembry 200 mgCSL Behring
- IcelandAndembryCSL Behring GmbH*
- NetherlandsANDEMBRY 200 mg oplossing voor injectie in voorgevulde penCSL Behring GmbH
- PolandAndembryCSL Behring GmbH
- SwedenANDEMBRY 200 mg Injektionsvätska, lösning i förfylld injektionspennaCSL Behring GmbH
- FinlandANDEMBRYCSL Behring GmbH
- IrelandANDEMBRY 200 mg solution for injection in pre-filled penCSL Behring GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Andembry
- Liechtenstein · Andembry
- Norway · Andembry
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b18ca5a2-21f9-44c2-a35b-a1d0d70aed83 GET /v1/drugs/b18ca5a2-21f9-44c2-a35b-a1d0d70aed83?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "garadacimabum 200 mg",
"valid_from": "2025-09-01",
"limitations": "[{\"description\":\"Nach Kostengutsprache des Krankenversicherers mit vorgängiger Konsultation des Vertrauensarztes resp. nach Kostengutsprache durch die IV-Stelle nach vorgängiger Konsultation des regionalärztlichen Dienstes (RAD).<br>\\nANDEMBRY wird vergütet als Monotherapie zur <b>Langzeitprophylaxe</b> wiederkehrender akuter Schübe des hereditären Angioödems (HAE) vom Typ I oder Typ II bei Patienten ab einem Alter von 12 Jahren, die trotz on-demand Behandlung einen nachweislich schweren Verlauf UND ≥ 2 Attacken pro Monat über einen Zeitraum von 12 Monaten verzeichnen.<br>\\nDie Einleitung und Überwachung der Behandlung erfolgt ausschliesslich über eines der folgenden Zentren: Universitätsspital Zürich, Inselspital Bern, Universitätsspital Basel, CHUV, HUG, Kantonsspi-tal Luzern, Kantonsspital Aarau und Kantonsspital St. Gallen, Hôpital du Valais (Institut Central des Hôpitaux (ICH) Sion und Ospedale Regionale di Bellinzona e Valli.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-09-01\",\"validTo\":\"2028-08-31\"}]",
"galenic_form": "Inj Lös 200 mg/1.2ml Fertpen",
"therapeutic_area": null,
"sl_inclusion_date": "2025-09-01",
"self_retention_pct": 10
}See everything about garadacimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.